Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ADC Therapeutics

Request full access

Develops proprietary antibody drugs targeting cancer

Epalinges, SwitzerlandFounded 2011Biotech & Life Sciences

About ADC Therapeutics

ADCT Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs are a type of targeted therapy that delivers potent drugs directly to cancer cells, minimizing damage to healthy cells. The company's primary focus is on hematologic malignancies, or cancers that affect the blood, bone marrow, and lymph nodes.

ADCT Therapeutics operates in the global pharmaceutical market, specifically within the oncology sector. Its clients are primarily healthcare providers and patients suffering from cancer. The company's business model revolves around the research, development, and commercialization of its ADCs. It generates revenue through the sales of its approved drugs and also through partnerships with other pharmaceutical companies for the development and commercialization of its drug candidates.

The company is committed to ethical practices, innovation, accountability, collaboration, and proactive action. It offers competitive salaries, bonuses, and comprehensive benefits programs to its employees, including a 401-K savings plan for US-based employees and a contributory pension for European-based employees.

ADCT Therapeutics is a publicly-traded company, and it recently reported its Q3 2023 financial results. The company's leadership participates in healthcare conferences and workshops, and it supports initiatives like The Leukemia and Lymphoma Society's Light the Night Walk.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020

ADC Therapeutics in the Epalinges ecosystem

Live from Dealroom

The ADC Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Auven Therapeutics
  • MedImmune

Series B and later6 investors entered at this stage

  • Spirogen
  • AstraZeneca
  • Wild Family Office
  • Redmile Group
  • Blue Owl Capital
  • Oaktree Capital Management
Employees mapped 262 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 27 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$58M

33 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See ADC Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.